Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged ≥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old

NCT04863638 is registered in ClinicalTrials.gov with China National Biotec Group Company Limited as lead sponsor.

NCT NCT04863638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04863638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged ≥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old
Lead sponsor
China National Biotec Group Company Limited
Phase
Phase 4
Overall status
Unknown status
Start date
April 29, 2021
Completion date
March 31, 2024
Enrollment
4,400 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19